The ACF is just a small part of the enormous 'cancer research ecosystem'.
We seek to do more with less
The ACF is just a small part of the enormous cancer research ecosystem. We cannot act alone. As an independent non-profit organisation, it is our responsibility to support collaboration and facilitate synergies, as we can do more if we work together. Money for cancer research should be spent as efficiently as possible. Knowledge should be shared and expertise made available across all boundaries.
Engagement with other non-profit organisations
Cancer organisations all work toward the same goal: finding a cure for cancer, increasing the number of treatment options available and enhancing quality of life of cancer patients. But, funding is required for progress. The better we can coordinate use of funding, the greater the return to patients.
Joint funding of clinical trials
Trials can be extremely expensive, and multiple funding sources may be needed. The ACF encourages, facilitates and catalyses co-funding models. For example, the Alexine Clarysse Fund and KickCancer co-fund the Metro-PD1 trial. Also pharmaceutical companies grant support to trials we are involved in, even though they wouldn't initiate such trials themselves: read more.
“As the main cancer organisation in Flanders (Belgium), Kom op tegen Kanker is proud to co-fund trials with the Anticancer Fund, such as the PRIMMO trial. Working together strengthens our impact.”
Some cancer organisations are too small to organise research. In many cases, we put our structure and expertise at their disposal. We discuss how we can invest their resources in research that aligns with their mission, and openly collaborate on study design, progress, etc. Funding is transferred 1-1 and invested in research. Operational costs are supported by the ACF, thanks to its founder Luc Verelst.
We invest in the most promising research to make measurable progress in the fight against cancer.
We strive to improve survival and quality of life, financial return is not within the scope of our activities.
We identify untapped potential in cancer research leading to pragmatic solutions for patients in need.
We seek impact and we invest our resources where we believe we can make the most progress.
Every cancer deserves the same attention, regardless of prevalence or profitability.